B-cell Acute Lymphoblastic Leukemia (B-ALL)
10
6
7
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (10)
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)